Cancer Stat Facts: Myeloma. National Cancer Institute, Surveillance, Epidemiology and End Results Program. Available: https://seer.cancer.gov/statfacts/html/mulmy.html. Accessed June 27, 2022.
Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014;28:1122–8. https://doi.org/10.1038/leu.2013.313.
Nguyen QD, Moodie EM, Forget MF, Desmarais P, Keezer MR, Wolfson C. Health Heterogeneity in Older Adults: Exploration in the Canadian Longitudinal Study on Aging. J Am Geriatr Soc 2021;69:678–87. https://doi.org/10.1111/jgs.16919.
Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci. 2004;59:255–63.
Ahmed N, Mandel R, Fain MJ. Frailty: an emerging geriatric syndrome. Am J Med. 2007;120:748–53. https://doi.org/10.1016/j.amjmed.2006.10.018.
Mian H, Brouwers M, Kouroukis CT, Wildes TM. Comparison of Frailty Scores in Newly Diagnosed Patients with Multiple Myeloma: A Review. J Frailty. Aging 2019;8:215–21.
Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in Older Adults: Evidence for a Phenotype. J Gerontology: Ser A 2001;56:M146–M57.
Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci. 2007;62:722–7.
Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 2015;125:2068–74.
Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia 2020;34:224–33.
Mian HS, Giri S, Wildes TM, Balitsky AK, McCurdy A, Pond GR, et al. External validation of the FIRST trial’s simplified frailty score in a population-based cohort. Leukemia. 2021;35:1823–7.
Monika E, Sandra Maria D, Gabriele I, Alexander Z, Mandy M, Heike R, et al. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica. 2016;101:1110–9.
Cook G, Larocca A, Facon T, Zweegman S, Engelhardt M. Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network. Leukemia 2020;34:2285–94.
Möller M-D, Gengenbach L, Graziani G, Greil C, Wäsch R, Engelhardt M Geriatric assessments and frailty scores in multiple myeloma patients: a needed tool for individualized treatment? Curr Opin Oncol. 2021;33.
Stege CAM, van der Holt B, Dinmohamed AG, Sonneveld P, Levin MD, van de Donk N, et al. Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities. Leukemia 2020;34:1964–6.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021;372:n71.
Klepin HD, Wildes TM. Fighting for the integration of geriatric principles into oncology. J Geriatr Oncol. 2018;9:705–6.
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538–48.
Auner HW, Brown SR, Walker K, Kendall J, Dawkins B, Meads D, et al. Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results. Blood. Cancer J. 2022;12:52.
Jackson GH, Pawlyn C, Cairns DA, Striha A, Collett C, Waterhouse A, et al. Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. Br J Haematol. 2021;192:853–68.
Tuchman SA, Moore JO, DeCastro CD, Li Z, Sellars E, Kang Y, et al. Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone (“VCD-Lite”) in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma. J Geriatr Oncol 2017;8:165–9.
Mele G, Giannotta A, Pinna S, Loseto G, Coppi MR, Brocca CM, et al. Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide. Leuk Lymphoma. 2010;51:937–40.
Jprn U. Phase 2 study to evaluate the efficacy and the safety of clarithromycin, lenalidomide and dexamethasone (Personalized BiRd) for patients with relapsed or refractory multiple myeloma. https://trialsearchwhoint/Trial2aspx?TrialID=JPRN UMIN000013467. 2014.
Stege CAM, Nasserinejad K, Levin MD, Klein SK, De Waal E, Eeltink C, et al. Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) – Results of the Dutch HOVON 123 Study. Blood 2018;132:4.
Larocca A, Bonello F, Gaidano G, D’Agostino M, Offidani M, Cascavilla N, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood 2021;137:3027–36.
Mina R, Larocca A, Offidani M, Innao V, Cellini C, Galli M, et al. Efficacy and Safety of Ixazomib Induction and Maintenance in Newly Diagnosed Multiple Myeloma Patients According to the IMWG Frailty Score: A Post-Hoc Analysis of the EMN10-Unito Trial. Blood. 2020;136:44–5.
Cook G, Pawlyn C, Royle KL, Coulson AB, Bird J, Bowcock S, et al. Fitness, a uk myeloma research alliance (UK-mra) frailty-adjusted therapy study, supports the feasibility of recruiting frail newly diagnosed myeloma patients to large clinical trials. Blood 2021;138:81.
Bringhen S, Pour L, Benjamin R, Grosicki S, Min CK, De Farias DLC, et al. Progression-free survival (PFS) benefit demonstrated and quality of life (QoL) maintained across age and frailty subgroups with the oral proteasome inhibitor (PI) ixazomib vs placebo as post-induction maintenance therapy in non-transplant newly diagnosed multiple myeloma (NDMM) patients (pts): Analysis of the TOURMALINE-MM4 phase 3 trial. Blood 2020;136:30–1.
Bringhen S, D’Agostino M, Paris L, Ballanti S, Pescosta N, Spada S, et al. Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. Haematologica 2020;105:1937–47.
Nct. Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy. https://www.clinicaltrials.gov/ct2/show/NCT03993912. 2019.
Facon T, Cook G, Usmani SZ, Hulin C, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022;02:02. https://doi.org/10.1038/s41375-021-01488-8.
Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Knop S, Doyen C, et al. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE. Clin Lymphoma Myeloma Leuk. 2021;21:785–98.
Zweegman S, Stege CAM, Haukas E, Schjesvold FH, Levin MD, Waage A, et al. Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. Haematologica 2020;105:2879–82.
Stege CAM, van der Holt B, Mellqvist U-H, Levin M-D, Salomo M, Abildgaard N, et al. Frailty Predicts Survival and Toxicity in Newly Diagnosed Multiple Myeloma Patients Ineligible for Autologous Stem Cell Transplantation; Report of the HOVON-87/Nmsg-18 Study Group. Blood 2017;130:3146.
Touzeau CA. Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse. IFM 2021_03. NCT04998786. https://clinicaltrials.gov/ct2/show/NCT04998786.
Macro M, Touzeau C, Mariette C, Manier S, Brechignac S, Vincent L, et al. Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail RRMM patients. a multicenter phase 2 study (IFM 2018-02) of the intergroupe francophone du myelome (IFM). Blood 2021;138:83.
Lee HS, Kim K, Kim SJ, Lee JJ, Kim I, Kim JS, et al. Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study). Am J Hematol. 2020;95:413–21.
Waldschmidt JM, Keller A, Ihorst G, Grishina O, Muller S, Wider D, et al. Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma). Haematologica 2018;103:e473–e9.
Lee HS Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone (LENDER). NCT03809780. https://clinicaltrials.gov/ct2/show/NCT03809780.
Nakazato T, Hagihara M, Sahara N, Tamai Y, Ishii R, Tamaki S, et al. Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma. Ann Hematol. 2021;100:2745–54.
O’Donnell EK, Suman VJ, Geyer SM, Nadeem O, Dinner S, Yee AJ, et al. A phase ii study of lenalidomide, ixazomib, dexamethasone, and daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (AFT-41). Blood 2021;138:4776.
A randomized m, open label study comparing two standard treatments, bortezomib-melphalan-prednisone (VMP) vs lenalidomide-dexamethasone (Rd) in autologous stem cell transplantation (ASCT) ineligible community population affected by multiple myeloma (MM). https://clinicaltrials.gov/ct2/show/NCT03829371.
Bao L, Lu M, Liu P, Zhuang J, Zhang M, Xia Z, et al. P-160: Efficacy and safety of induction therapy with IAd versus IRd regimen in fragile elderly patients with newly diagnosed multiple myeloma: results of a prospective multicenter clinical trail. Clin Lymphoma, Myeloma Leuk. 2021;21:S123 https://doi.org/10.1016/S2152-2650%2821%2902287-4.
Auner HW, Gavriatopoulou M, Delimpasi S, Simonova M, Spicka I, Pour L, et al. Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. Am J Hematol. 2021;96:708–18.
Schjesvold F, Bringhen S, P GR, Perrot A, Leleu X, Moreau P, et al. Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Am J Hematol. 2021;96:E423–E7.
Facon T, Niesvizky R, Mateos MV, Siegel D, Rosenbaum C, Bringhen S, et al. Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. Blood Adv. 2020;4:5449–59.
Quach H, Leleu X, Mateos M-V, Usmani SZ, Nooka AK, Goldrick A, et al. P907: Carfilzomib, Dexamethasone, and Daratumumab (KDD) vs Carfilzomib and Dexamethasone (KD) in Relapsed/refractory multiple myeloma (RRMM): Frailty subgroup analysis of the Candor study. EHA 2022.
Oriol Rocafiguera A, Dimopoulos MA, Schjesvold F, Beksac M, Yagci M, Larocca A, et al. Pomalidomide, bortezomib, and dexamethasone in lenalidomide-pretreated multiple myeloma: A subanalysis of OPTIMISMM by frailty. J Clin Oncol. 2022;40:8024. https://doi.org/10.1200/JCO.2022.40.16_suppl.8024.
Stege CAM, Nasserinejad K, van der Spek E, Bilgin YM, Kentos A, Sohne M, et al. Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study. J Clin Oncol. 2021;39:2758–67.
Mina R, Larocca A, Corradini P, Cascavilla N, Liberati AM, Pescosta N, et al. Ixazomib-based induction followed by single-agent ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma patients: Updated results of the EMN10-unito trial. HemaSphere 2021;5:27–8.
Brioli A, Manz K, Pfirrmann M, Hanel M, Schwarzer AC, Prange-Krex G, et al. Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN). J Cancer Res Clin Oncol. 2020;146:749–59.
Larocca A, Petrucci MT, Conticello C, De Paoli L, D’Agostino M, Spada S, et al. Updated results of a phase ii study with carfilzomib, cyclophosphamide and dexamethasone (CCD) for newly diagnosed transplant ineligible multiple myeloma patients. HemaSphere 2018;2:234.
Tyler D. Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy in Elderly, Frail Newly Diagnosed Myeloma (MMY2035) NCT04223661. https://clinicaltrials.gov/ct2/show/NCT04223661.
Stege CA, Seefat M, Levin MD, Timmers GJ, Hoogendoorn M, Ypma P, et al. Health-related quality of life in unfit and frail newly diagnosed multiple myeloma patients treated with dose-adjusted melphalan-prednisone-bortezomib. HemaSphere 2021;5:487–8.
Giri S, Williams G, Rosko A, Grant SJ, Mian HS, Tuchman S, et al. Simplified frailty assessment tools: Are we really capturing frailty or something else? Leukemia 2020;34:1967–9.
Stege CAM, Nasserinejad K, Klein SK, Timmers G-J, Hoogendoorn M, Ypma PF, et al. Improving the identification of frail elderly newly diagnosed multiple myeloma patients. Leukemia. 2021;35:2715–9.
Herrera AP, Snipes SA, King DW, Torres-Vigil I, Goldberg DS, Weinberg AD. Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. Am J Public Health 2010;100:S105–12.
Chindapasirt J. Sarcopenia in Cancer Patients. Asian Pac J Cancer Prev. 2015;16:8075–7.
Möller MK-GM, Ihorst G, Gengenbach L, Barsch F, Pahl A, Jung J, et al. A randomized, controlled clinical trial (RCT) to evaluate the safety and feasibility of physical activity (PA) in patients (pts) with newly diagnosed Multiple Myeloma (NDMM) (REAL-FITNESS). DGH0 2021.
Frailty-stratified, randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma (TI-NDMM) a[Euro sign]” the FRAIL-M study. http://www.amarconline.org/clinical-trials/frailm.
Groen K, Stege CAM, Nasserinejad K, de Heer K, Van Kampen RJW, Leijs MBL, et al. Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study. Blood. 2021;138:80.
Cohen Y Safety, Tolerability, and Efficacy of Once Weekly Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone, in Transplant-ineligible Multiple Myeloma Patients Non-responsive to a Bortezomib Based Induction. NCT04065789. https://clinicaltrials.gov/ct2/show/NCT04065789. 2019.
Feasibility and efficacy of triplet regimen in transplant-ineligible NDMM patients (JPRN-UMIN000027978). https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000027978.
Larocca A, Bringhen S, Petrucci MT, Oliva S, Falcone AP, Caravita T, et al. A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. Leukemia 2016;30:1320–6.
Ludwig H, Poenisch W, Egle A, Knop S, Schreder M, Lechner D, et al. Ixazomib in combination with thalidomide and dexamethasone for induction and ixazomib maintenance therapy in patients with relapsed/refractory multiple myeloma. HemaSphere 2018;2:602.
Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT). NCT03748953. https://clinicaltrials.gov/ct2/show/NCT03748953.
link